PARIS, 3 juin (Reuters) - L action Innate Pharma reprend le chemin de la hausse mercredi alors que le titre de la société de biotechnologie en avait perdu en début de semaine...
André Choulika does not mince words. The Cellectis CEO is an outspoken champion of all things related to the company he founded 15 years ago.
Axovant Sciences, heading toward Phase III with an ex-GlaxoSmithKline treatment for Alzheimer's disease, has upped its IPO hopes to more than $300 million, betting it can win FDA approval where many others have failed.
LUND, Sweden, June 1, 2015 -- Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the company has made a notification of planned redundancies of 47 of its employees, which means a...
"The collaboration will draw on L’Oreal’s experience in beauty product development and Organovo’s proprietary NovoGen Bioprinting Platform to grow bioprinted skin for product testing."
Puma Biotechnology, Inc. , a development stage biopharmaceutical company, announced the presentation of positive results from the Phase III clinical trial of Puma's investigational drug PB272 for the extended adjuvant treatment of breast cancer .
State government will promote biotechnology industry in UP.
Orphan drug designation comes with many perks, including sky-high prices and protection from generic competition
Les marchés financiers continuent toujours et encore de vivre au gré des nouvelles en provenance de Grèce...
Pfizer, numéro un mondial de la pharmacie qui détient déjà 9,47% de Cellectis, a contacté la société en vue d'une fusion, avec une proposition pour un montant de 1,5 milliard d'euros, d'après le Financial Times.